Notice of GM

Renalytix PLC
03 April 2024
 

 

Renalytix plc

("Renalytix" or the "Company")

 

Notice of General Meeting

 

LONDON and SALT LAKE CITY, April 3, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimising clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that a General Meeting ("GM") will be held on 22 April 2024 at 3.00 p.m. (BST) at 6 Stratton Street Mayfair, London W1J 8LD.

 

A proxy statement (including the notice of GM) will be posted to shareholders who have not consented to receive electronic communications later today and is now available to view on the Company website:

 https://investors.renalytix.com/news-and-events/documents-and-presentations

 

Hard copies of the form of proxy for the General Meeting will only be available upon request and instead, voting can be done electronically using the link www.signalshares.com. Investors will need to log into their Signal Shares account or register if they have not previously done so. All details about how to vote can be found in the notice of GM.

 

To help with practical arrangements for the GM, any shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com.

 

For further information, please contact:

 

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

 

 

Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654

 

 

CapComm Partners

 

Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100